Display options
Cite
García M, Kokkinou E, Carrasco García A, et al. Innate lymphoid cell composition associates with COVID-19 disease severity. Clin Transl Immunology. 2020;9(12):e1224doi: 10.1002/cti2.1224.
García, M., Kokkinou, E., Carrasco García, A., Parrot, T., Palma Medina, L. M., Maleki, K. T., Christ, W., Varnaitė, R., Filipovic, I., Ljunggren, H. G., Björkström, N. K., Folkesson, E., Rooyackers, O., Eriksson, L. I., Sönnerborg, A., Aleman, S., Strålin, K., Gredmark-Russ, S., Klingström, J., Mjösberg, J. (2020). Innate lymphoid cell composition associates with COVID-19 disease severity. Clinical & translational immunology, 9(12), e1224. https://doi.org/10.1002/cti2.1224
García, Marina, et al. "Innate lymphoid cell composition associates with COVID-19 disease severity." Clinical & translational immunology vol. 9,12 (2020): e1224. doi: https://doi.org/10.1002/cti2.1224
García M, Kokkinou E, Carrasco García A, Parrot T, Palma Medina LM, Maleki KT, Christ W, Varnaitė R, Filipovic I, Ljunggren HG, Björkström NK, Folkesson E, Rooyackers O, Eriksson LI, Sönnerborg A, Aleman S, Strålin K, Gredmark-Russ S, Klingström J, Mjösberg J. Innate lymphoid cell composition associates with COVID-19 disease severity. Clin Transl Immunology. 2020 Dec 14;9(12):e1224. doi: 10.1002/cti2.1224. eCollection 2020. PMID: 33343897; PMCID: PMC7734472.
Copy Download .nbib Format: NLM
Share it on

Clin Transl Immunology. 2020 Dec 14;9(12):e1224. doi: 10.1002/cti2.1224. eCollection 2020.

Innate lymphoid cell composition associates with COVID-19 disease severity.

Clinical & translational immunology

Marina García, Efthymia Kokkinou, Anna Carrasco García, Tiphaine Parrot, Laura M Palma Medina, Kimia T Maleki, Wanda Christ, Renata Varnaitė, Iva Filipovic, Hans-Gustaf Ljunggren, Niklas K Björkström, Elin Folkesson, Olav Rooyackers, Lars I Eriksson, Anders Sönnerborg, Soo Aleman, Kristoffer Strålin, Sara Gredmark-Russ, Jonas Klingström, Jenny Mjösberg,

Affiliations

  1. Department of Medicine Huddinge Center for Infectious Medicine Karolinska Institutet Karolinska University Hospital Stockholm Sweden.
  2. Department of Infectious Diseases Karolinska University Hospital Stockholm Sweden.
  3. Department of Medicine Solna Division of Infectious Diseases Karolinska Institutet Stockholm Sweden.
  4. Department of Clinical Science, Technology and Intervention Division of Anesthesiology and Intensive Care Karolinska Institutet Huddinge Sweden.
  5. Function Perioperative Medicine and Intensive Care Karolinska University Hospital Stockholm Sweden.
  6. Department of Physiology and Pharmacology Section for Anesthesiology and Intensive Care Karolinska Institutet Stockholm Sweden.
  7. Division of Infectious Diseases and Dermatology Department of Medicine Huddinge Karolinska Institutet Stockholm Sweden.

PMID: 33343897 PMCID: PMC7734472 DOI: 10.1002/cti2.1224

Abstract

OBJECTIVES: The role of innate lymphoid cells (ILCs) in coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is unknown. Understanding the immune response in COVID-19 could contribute to unravel the pathogenesis and identification of treatment targets. Here, we describe the phenotypic landscape of circulating ILCs in COVID-19 patients and identified ILC phenotypes correlated to serum biomarkers, clinical markers and laboratory parameters relevant in COVID-19.

METHODS: Blood samples collected from moderately (

RESULTS: Innate lymphoid cells were largely depleted from the circulation of COVID-19 patients compared with healthy controls. Remaining circulating ILCs revealed decreased frequencies of ILC2 in severe COVID-19, with a concomitant decrease of ILC precursors (ILCp) in all patients, compared with controls. ILC2 and ILCp showed an activated phenotype with increased CD69 expression, whereas expression levels of the chemokine receptors CXCR3 and CCR4 were significantly altered in ILC2 and ILCp, and ILC1, respectively. The activated ILC profile of COVID-19 patients was associated with soluble inflammatory markers, while frequencies of ILC subsets were correlated with laboratory parameters that reflect the disease severity.

CONCLUSION: This study provides insights into the potential role of ILCs in immune responses against SARS-CoV-2, particularly linked to the severity of COVID-19.

© 2020 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc.

Keywords: COVID‐19; SARS‐CoV‐2; coronavirus; immune response; innate lymphoid cells; respiratory viral infection

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. HGL is a member of the boar

References

  1. Lancet. 2020 Mar 28;395(10229):1054-1062 - PubMed
  2. Nat Immunol. 2011 Nov;12(11):1045-54 - PubMed
  3. PLoS Comput Biol. 2018 Jan 31;14(1):e1005973 - PubMed
  4. J Immunol. 2016 Mar 1;196(5):2051-2062 - PubMed
  5. Nature. 2010 Jan 28;463(7280):540-4 - PubMed
  6. Sci Immunol. 2020 Jul 15;5(49): - PubMed
  7. J Immunol. 2020 Nov 1;205(9):2437-2446 - PubMed
  8. Cytokine. 2020 Sep;133:155151 - PubMed
  9. J Clin Invest. 2020 May 1;130(5):2620-2629 - PubMed
  10. Nature. 2020 Mar;579(7798):270-273 - PubMed
  11. J Neurovirol. 2017 Dec;23(6):845-854 - PubMed
  12. J Gen Virol. 2011 Oct;92(Pt 10):2237-2248 - PubMed
  13. Nature. 2010 Apr 29;464(7293):1367-70 - PubMed
  14. Nat Immunol. 2013 Mar;14(3):221-9 - PubMed
  15. J Infect Dis. 2020 May 11;221(11):1762-1769 - PubMed
  16. Eur J Immunol. 2019 Jan;49(1):144-156 - PubMed
  17. Autoimmun Rev. 2020 Jul;19(7):102569 - PubMed
  18. Cell Rep. 2017 Sep 19;20(12):2921-2934 - PubMed
  19. Cell. 2020 Oct 1;183(1):158-168.e14 - PubMed
  20. Cell. 2018 Aug 23;174(5):1054-1066 - PubMed
  21. Cell. 2017 Mar 9;168(6):1086-1100.e10 - PubMed
  22. J Allergy Clin Immunol. 2019 Jul;144(1):61-69.e7 - PubMed
  23. Sci Immunol. 2020 Aug 21;5(50): - PubMed
  24. Clin Infect Dis. 2020 Jul 28;71(15):762-768 - PubMed
  25. Oncotarget. 2015 Oct 13;6(31):32138-53 - PubMed
  26. Cell. 2017 Nov 2;171(4):795-808.e12 - PubMed
  27. Immunity. 2012 Oct 19;37(4):649-59 - PubMed
  28. J Clin Virol. 2020 Jun;127:104370 - PubMed
  29. Nat Rev Drug Discov. 2020 May;19(5):305-306 - PubMed
  30. Gastroenterology. 2020 Jul;159(1):81-95 - PubMed
  31. Immunity. 2019 Feb 19;50(2):505-519.e4 - PubMed
  32. Front Immunol. 2020 May 07;11:691 - PubMed
  33. Front Cell Infect Microbiol. 2019 Jun 13;9:207 - PubMed
  34. N Engl J Med. 2020 Sep 3;383(10):992-993 - PubMed
  35. Allergy. 2020 Jul;75(7):1564-1581 - PubMed
  36. Int J Infect Dis. 2020 Jun;95:304-307 - PubMed
  37. Immunity. 2016 Feb 16;44(2):391-405 - PubMed
  38. Proc Natl Acad Sci U S A. 2010 Jun 22;107(25):11489-94 - PubMed
  39. Sci Immunol. 2019 Nov 8;4(41): - PubMed
  40. Lancet. 2020 Feb 15;395(10223):497-506 - PubMed
  41. Mod Pathol. 2020 Nov;33(11):2104-2114 - PubMed
  42. J Crohns Colitis. 2019 Jan 1;13(1):67-78 - PubMed
  43. Nature. 2013 Feb 14;494(7436):261-5 - PubMed
  44. Front Immunol. 2013 Oct 08;4:289 - PubMed
  45. Immunity. 2017 Jan 17;46(1):148-161 - PubMed
  46. Lancet. 2020 Mar 28;395(10229):1033-1034 - PubMed
  47. J Infect Dis. 2019 May 5;219(11):1832-1840 - PubMed
  48. Immunity. 2008 Dec 19;29(6):958-70 - PubMed
  49. Science. 2020 Jul 3;369(6499):50-54 - PubMed
  50. Nat Immunol. 2020 Apr;21(4):412-421 - PubMed
  51. J Virol. 2010 Apr;84(8):4073-82 - PubMed
  52. Nature. 2020 Oct;586(7827):113-119 - PubMed
  53. Gastroenterology. 2020 May;158(6):1831-1833.e3 - PubMed
  54. Nature. 2020 Jul;583(7816):437-440 - PubMed

Publication Types